Utilizing this unique animal model of thrombosis we demonstrated that human (IgG, IgM or IgA) polyclonal and monoclonal antiphospholipid antibodies derived from APS patients have a significant enhancing effect on thrombus formation. This effect is reversed by treatment of the mice with hydroxychloroquine (plaquenil). In addition murine polyclonal and monoclonal anticardiolipin antibodies induced by active immunization with human β2-GP1 or human anticardiolipin antibodies showed to have thrombogenic properties in CD1 mice. Antibodies with antihuman β2-GP1 activity alone did not seem to affect thrombus formation.
HughesGRVHarrisENGharaviAE. The anti-cardiolipin syndrome. J Rheumatol1986; 13: 486–489
8.
AshersonRA. A ‘primary’ antiphospholipid syndrome?. J Rheumatol1988; 15: 1742–1746
9.
HarrisENThrombosis, recurrent fetal loss, and thrombocytopenia: predictive value of IgG anticardiolipin antibodies. Arch Intern Med1986; 146: 2153–2156
10.
AlvingBMBarrCFTangDB. Correlation between lupus anticoagulants and anticardiolipin antibodies in patients with prolonged activated partial thromboplastin times. Am J Med1990; 88: 112–116
11.
LockshinMDQamarTDruzinMGoeiS. Antibody to cardiolipin, lupus anticoagulant, and fetal death. J Rheumatol1987; 14: 259–262
12.
LoizouSAssociation of quantitative anti-cardiolipin antibody levels with fetal loss. Quart J Med1988; 68: 525–531
13.
CompPCDebaultLEEsmonNLEsmonCT. Human thrombomodulin is inhibited by IgG from two patients with non-specific anticoagulants. Blood1983; 62: 299a
14.
FreyssinetJMAn IgM lupus anticoagulant that reutilizes the enhancing effect of phospholipid on purified thrombomodulin activity. A mechanism for thrombosis. Thromb Haemost1986; 55: 309–313
15.
CariouREffect of the lupus anticoagulant on antithrombogenic properties of endothelial cells-inhibition of thrombomodulin dependent protein C activation. Thromb Haemost1985; 60: 54–58
16.
MarciniakERomondEH. Impaired catalytic function of activated protein C: A new in vitro manifestation of lupus anticoagulant. Blood1989; 74: 2426–2432
CampbellALPierangeliSSWellhausenSHarrisEN. Comparison of the effect of anticardiolipin antibodies from patients with the Antiphospholipid Syndrome and with syphilis on platelet activation and aggregation. Thromb Haemost1995; 73 (3): 529–524
19.
GalliMAnticoagulant activity of β2-glycoprotein 1 is potentiated by a distinct subgroup of anticardiolipin antibodies. Thromb Haemost1992; 68: 297–300
20.
BranchDWIgG fraction from patients with antiphospholipid antibodies cause fetal death in BALB/c mice: a model for autoimmune fetal death. Am J Obtet Gynecol1990; 163: 420
21.
BlankMCohenJToderVShoenfeldY. Induction of antiphospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anticardiolipin antibodies. Proc Natl Acad Sci USA1991; 88: 3069–3073
22.
MendlovicSInduction of systemic lupus erythematosus-like diseases by a common human antiDNA idiotype. Proc Natl Acad Sci USA1988; 85: 2260–2264
23.
BakimerRInduction of primary antiphospholipid syndrome in mice by immunization with a human monoclonal anticardiolipin antibody. J Clin Invest1992; 89: 1558–1563
24.
SthoegerZWTartakovskyBBentwichZMozesE. Monoclonal anticardiolipin antibodies derived from mice with experimental lupus erythematosus: characterization and the induction of a secondary antiphospholipid syndrome. J Clin Immunol1993; 13: 127–138
25.
FishmanPPrevention of fetal loss in experimental antiphospholipid syndrome by in vivo administration of recombinant interlekin-3. J Clin Invest1993; 91: 1834–1837
26.
BlankMImmunization with anticardiolipin cofactor (β2-glycoprotein 1) induces experimental APS in naive mice. Arthr Rheum1993; 36 (9): S134
27.
SilverRMInduction of high levels of anticardiolipin antibodies in mice by immunization with β2-glycoprotein 1(β2-GP1) does not cause fetal death. Am J Obstet Gynecol1995; 173: 1410–1415
28.
SmithHRHansenCLRoseRCanosoRT. Autoimmune MRL/lpr/lpr mice are an animal model for the secondary antiphospholipid syndrome. J Rheumatol1990; 17: 911–515
29.
StockmansFContinuous quantitative monitoring of mural thrombus kinetics in the crushed rat femoral vein. Thromb Haemost1991; 65: 425–431
30.
PierangeliSSEffect of human IgG antiphospholipid antibodies on an in vivo thrombosis model in mice. Thromb Haemost1994; 71 (5): 670–674
31.
PierangeliSSInduction of thrombosis in a mouse model by IgG, IgM and IgA immunoglobulins from patients with the Antiphospholipid Syndrome. Thromb Haemost1995; 74: 1361–1367
32.
OleeTA monoclonal IgG anticardiolipin antibody from a patient with Antiphospholipid Syndrome is thrombogenic in miceProc Natl Acad Sci USA1996 (in press)
33.
McNeilHPSimpsonRJChestermanCNKrilisS. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein 1 (apolipoprotein H). Proc Natl Acad Sci USA1990; 87: 4120–4124
34.
PierangeliSSHarrisENDavisSADeLorenzoG. β2-glycoprotein 1 enhances cardiolipin binding activity but is not the target antigen for antiphospholipid antibodies. Br J Haematol1992; 82: 565–570
35.
SammaritanoLRLockshinMDGharaviAE. Antiphospholipid antibodies differ in aPL cofactor requirementLupus1992; 1: 51–56
36.
GharaviAESammaritanoLRWenJElkonKB. Induction of antiphospholipid autoantibodies by immunization with β2-glycoprotein 1. J Clin Invest1992; 90: 1105–1109
37.
PierangeliSSDavisSAHarrisEN. Induction of phospholipid binding antibodies in mice and rabbits by immunization with human β2-glycoprotein 1 or anticardiolipin antibodies alone. Clin Exp Immunol1993; 93 (2): 269–272
38.
NimpfJWurmHKostnerGM. 2glycoprotein 1 (apo H) inhibits the release reaction of human platelets during ADP-induced aggregation. Atherosclerosis1987; 63: 109
39.
PierangeliSSThrombogenic properties of murine anticardiolipin antibodies induced by β2-glycoprotein 2 and human IgG antiphospholipid antibodies. Circulation1996 (in Press)
40.
RosoveMHBrewerPMC. Antiphospholipid thrombosisL clinical course after the first thrombotic event in 70 patients. Ann Intern Med1992; 117: 303–308
41.
DerksenRHWMdeGrootPGKaterLNieuwenhuisHK. Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment. Ann Rheum Dis1993; 52: 689–692
42.
KhamashtaMAThe management of thrombosis in the antiphospholipid antibody syndrome. N Engl J Med1995; 332 (15): 993–997
43.
CarterAEbanR. Prevention of postoperative deep venous thrombosis in legs by orally administered hydroxychloroquine sulphate. Brit Med J1974; 3: 94–55
44.
JohnsonRGreenJCharnleyJ. Pulmonary embolism and its prophylaxis following the Charnley total hip replacementClin Orthop1977; 127: 123–132
45.
KniselyMBlochE. Microscopic observations of intravascular agglutination of red cells and consequent sludging of blood in human diseases. Anat Rec1942; 82: 426
46.
MadowB. Use of antimalarial drugs as ‘desludging agents in vascular disease processes‘. J Amer Med Assoc1990; 172: 1630–1833
47.
PetriMIncidence of and predictors of thrombotic events in SLE: protective role of hydroxychloroquine. Arthr Rheum1992; 35 (Suppl 9): S54
48.
WallaceD. Does hydroxychloroquine sulphate prevent clot formation in systemic lupus erythematosus?. Arthrit Rheum1987; 30: 1435–1436 (letter)
